Daewoong Pharmaceutical's Nabota (botulinum toxin type A) has surpassed 1 trillion won (approximately $750 million USD) in cumulative lifetime sales, underscoring the maturation and scale of the Asian aesthetics market. Nabota is the leading botulinum toxin in South Korea and has expanded into other Asian markets, competing against Botox and Dysport on price and local market knowledge.
Market
Daewoong's Nabota Hits 1 Trillion Won in Cumulative Sales—Asian Toxin Market Matures
South Korean botulinum toxin reaches milestone as Asian aesthetics market consolidates around regional players.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
1 trillion won in cumulative sales demonstrates the scale of regional toxin markets outside the U.S.
The milestone reflects a structural reality: non-Western markets are developing robust, locally-manufactured neuromodulator and filler ecosystems that compete on cost and regulatory familiarity. For U.S. practice owners, this signals that global supply chains for injectables are diversifying. If Asian manufacturers continue to gain share in their home markets, they will eventually seek U.S. entry—either through FDA approval or acquisition by larger players. Practitioners should view this as a long-term competitive pressure on pricing and a reminder that the AbbVie-Galderma duopoly is not inevitable.
Source: original report ↗
Frequently asked questions
What is Nabota and how much has it sold?
Nabota is a botulinum toxin type A manufactured by South Korean company Daewoong Pharmaceutical. It has achieved over 1 trillion won (approximately $750 million USD) in cumulative lifetime sales, making it the leading botulinum toxin in South Korea with expanding presence across Asian markets.
How does Nabota compete against Botox and Dysport?
Nabota competes primarily on price and local market knowledge in Asia, leveraging regional manufacturing and regulatory familiarity. As a locally-produced alternative, it undercuts Western brands while benefiting from established distribution networks and trust in South Korean and other Asian markets.
Will Asian botox brands enter the US market?
Asian manufacturers like Daewoong are likely to pursue U.S. entry through either FDA approval or acquisition by larger pharmaceutical companies as they consolidate market share in their home regions. This represents a long-term competitive threat to the current AbbVie-Galderma duopoly in the American aesthetics market.
What does the Asian toxin market milestone mean for US med spa pricing?
The maturation of regional injectable ecosystems signals long-term pricing pressure on U.S. practitioners as global supply chains diversify and new competitors emerge. Practice owners should expect competitive pricing dynamics to shift as non-Western manufacturers gain scale and potentially enter the U.S. market.
Is the Botox and Dysport duopoly in the US changing?
The rise of successful regional players like Nabota demonstrates that the AbbVie-Galderma duopoly is not inevitable. As Asian manufacturers prove viability and profitability in their home markets, they will increasingly target U.S. market entry, fragmenting the current two-player dominance.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.